Translate

Κυριακή 23 Ιουνίου 2019

Therapy


A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component
Summary Introduction We conducted a multicenter, phase 2 trial using gemcitabine plus axitinib (GX) in patients with recurrent or metastatic sarcomatoid renal cell carcinoma (SRCC) to evaluate its efficacy and safety. Methods Patients with advanced RCC and a sarcomatoid component of ≥25% on resected kidney or exclusive sarcomatoid carcinoma on needle biopsy were included. Patients received gemcitabine 1000 mg/m2 intravenously on days 1 and 8 of a 3-week cycle and axitinib 5 mg...
Latest Results for Investigational New Drugs
5h
Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer
Summary Purpose Sunitinib is a vascular endothelial growth factor receptor (VEGFR) inhibitor with antitumor activity against bladder cancer. We hypothesized that treatment with sunitinib may decrease progression or recurrence in non-muscle invasive bladder cancer (NMIBC) refractory to intra-vesical BCG. Patients and Methods This is a single-arm phase II study of sunitinib in patients (pts) with NMIBC who progressed after BCG. Treatment included sunitinib 37.5 g daily for 12 weeks...
Latest Results for Investigational New Drugs
5h
A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC
Summary Objective Apatinib is an oral small molecule anti-angiogenic drug. This phase I study aimed to establish the feasible dose of apatinib in combination with pemetrexed plus carboplatin as first-line therapy for epidermal growth factor receptor (EGFR) and anaplasticlymphoma kinase (ALK) negative stage IV non-squamous non-small cell lung cancer (NSCLC). Methods Using a 3 + 3 dose-reduction design, patients received oral apatinib at four dose levels: 750 mg qd, 500 mg qd, 500 mg/day...
Latest Results for Investigational New Drugs
5h
Protective effects of melatonin on sepsis-induced liver injury and dysregulation of gluconeogenesis in rats through activating SIRT1/STAT3 pathway
Publication date: September 2019Source: Biomedicine & Pharmacotherapy, Volume 117Author(s): Jian Chen, Hongzhen Xia, Lin Zhang, Huan Zhang, Di Wang, Xiaogen TaoAbstractSepsis, a life-threatening disease with high morbidity and mortality in critically ill patients, usually leads to serious complications including liver damage and dysregulated metabolic homoeostasis. The aim of this study was to evaluate the therapeutic potential of melatonin in rats with caecal ligation and puncture (CLP)-induced...
Biomedicine & Pharmacotherapy
1d
Long noncoding RNA SNHG16 promotes human retinoblastoma progression via sponging miR-140-5p
Publication date: September 2019Source: Biomedicine & Pharmacotherapy, Volume 117Author(s): Chunling Xu, Chunmei Hu, Yingxue Wang, Shu LiuAbstractSmall nucleolar RNA host gene 16 (SNHG16), a long non-coding RNA, was reported to function as an oncogene in multiple cancers. However, its biological function and regulatory mechanism in retinoblastoma (RB) has not yet been revealed. In this study, we attempted to ascertain the biological role and underlying regulatory mechanism of SNHG16 in RB progression....
Biomedicine & Pharmacotherapy
1d
Evaluation of the hepatoprotective, anti-inflammatory, antinociceptive and antiepileptic activities of <em>Chrysanthemum trifurcatum</em>
Publication date: September 2019Source: Biomedicine & Pharmacotherapy, Volume 117Author(s): Gamal A. Salem, Fathi B. Alamyel, Faraj A. Abushaala, khloud A. Elnory, Hawa Abusheba, Ravi P. SahuAbstractChrysanthemum trifurcatum is common to Mediterranean countries and widely-used in traditional medicine. Due to the scarcity of data about the pharmacological properties of C. trifurcatum, this present study was designed to determine the effects of C. trifurcatumethanolic extract (CEE) for its anti-nociceptive,...
Biomedicine & Pharmacotherapy
1d
GC/MS-based metabonomics approach reveals effects of Xuebijing injection in CLP induced septic rats
Publication date: September 2019Source: Biomedicine & Pharmacotherapy, Volume 117Author(s): Yu Jiang, Lianhong Zou, Sulai Liu, Xiehong Liu, Fang Chen, Xiaoliang Liu, Yimin ZhuAbstractXuebijing (XBJ) injection, a Chinese traditional medicine injection, is widely used in the treatment of sepsis in China, and shows a promising clinical therapeutic effect. However, its impacts on the metabolic changes of sepsis have not yet been reported. We established a septic rat model using cecal ligation and...
Biomedicine & Pharmacotherapy
1d
Traditional Chinese medicine combined with hepatic targeted drug delivery systems: A new strategy for the treatment of liver diseases
Publication date: September 2019Source: Biomedicine & Pharmacotherapy, Volume 117Author(s): Zhe Ma, Bing Zhang, Yuqi Fan, Meng Wang, Dereje Kebebe, Jiawei Li, Zhidong LiuAbstractLiver diseases are clinically common and present a substantial public health issue. Many of the currently available drugs for the treatment of liver diseases suffer from limitations that include low hepatic distribution, lack of target effects, poor in vivo stability and adverse effects on other organs. Consequently,...
Biomedicine & Pharmacotherapy
1d
Natural products for treating colorectal cancer: A mechanistic review
Publication date: September 2019Source: Biomedicine & Pharmacotherapy, Volume 117Author(s): Xuan-mei Huang, Zhi-jie Yang, Qing Xie, Zi-kang Zhang, Hua Zhang, Jun-ying MaAbstractColorectal cancer (CRC) is one of the most common types of cancers in humans and is closely linked to the global cancer-related mortalities worldwide. Molecular pathological epidemiology studies can reveal the risk factors of CRC and contribute to biomarker research and precision medicine. The current clinical treatment...
Biomedicine & Pharmacotherapy
1d
Recurrence rates for patients with early-stage breast cancer treated with IOERT at a community hospital per the ASTRO consensus statement for APBI
Publication date: Available online 22 June 2019Source: BrachytherapyAuthor(s): Venita L. Williams, Tanuja Bhandari, Lillian J. Chen, Lawrence D. Wagman, Michele Carpenter, Jay K. Harness, Rajesh Khanijou, Maher Gobran, Windy Olaya, Melissa I. Carandang, Robert B. AshAbstractPurposeTo report the recurrence rates after single-fraction intraoperative electron radiotherapy (IOERT) in patients with early-stage breast cancer treated on a single institution prospective Phase I/II protocol at a community...
Brachytherapy
1d
An improved treatment planning and quality assurance process for Collaborative Ocular Melanoma Study eye plaque brachytherapy
Publication date: Available online 22 June 2019Source: BrachytherapyAuthor(s): R.A. Weersink, S. Patterson, H. Ballantyne, A. Di Tomasso, J. Borg, A. Vitkin, A. Rink, A. Beiki-ArdakaniAbstractPurposeTo develop a treatment planning platform for episcleral Collaborative Ocular Melanoma Study plaque therapy in an established treatment planning software and to improve an existing quality assurance (QA) process for nonuniformly loaded plaques that measures air kerma strengths (AKSs) and loading profile.Materials...
Brachytherapy
1d
Lysophosphatidic acid induces interleukin-6 and CXCL15 secretion from MLO-Y4 cells through activation of the LPA<sub>1</sub> receptor and PKCθ signaling pathway
Publication date: September 2019Source: International Immunopharmacology, Volume 74Author(s): Xiangnan Wu, Yuanyuan Ma, Helin Chen, Zhichao Hao, Naichuan Su, Xiaoyu Li, Jiefei Shen, Hang WangAbstractLysophosphatidic acid (LPA) is a multifunctional phospholipid. Osteocytes are the most abundant cells in bone and can orchestrate bone formation and resorption, in part by producing cytokines that regulate osteoblast and osteoclast differentiation and activity. Interleukin (IL)-6 and IL-8 are two important...
ScienceDirect Publication: International Immunopharmacology
1d
Differential effects of inhaled <em>R-</em> and <em>S-</em>terbutaline in ovalbumin-induced asthmatic mice
Publication date: August 2019Source: International Immunopharmacology, Volume 73Author(s): Huimin Beng, Hao Su, Shanping Wang, Yihe Kuai, Junhua Hu, Rui Zhang, Fei Liu, Wen TanAbstractInhaled terbutaline is commercially available β2-agonist which consists of equivalent amount of R- and S-enantiomer. In this study, we aimed to investigate the effects of single enantiomers of terbutaline and its racemate in an ovalbumin (OVA)-induced mouse model of asthma via. seven days inhalation and the potential...
ScienceDirect Publication: International Immunopharmacology
1d
Antifungal Effect of Photodynamic Therapy Mediated by Curcumin on <em>Candida albicans</em> Biofilms <em>in Vitro</em>
Publication date: Available online 21 June 2019Source: Photodiagnosis and Photodynamic TherapyAuthor(s): Jing Ma, Hang Shi, Hongying Sun, Jiyang Li, Yu BaiAbstractBackground: Canida albicans can cause opportunistic infections ranging from superficial mucous membrane lesions to life-threatening diseases. The aim of this study is to investigate the antifungal effect of photodynamic therapy (PDT) mediated by curcumin (CUR) on C. albicans biofilms in vitro.Methods: One standard strain ATCC 90028 and...
ScienceDirect Publication: Photodiagnosis and Photodynamic Therapy
1d
Ocular preservation through limited tumor excision combined with ALA-PDT in patients with periocular basal cell carcinoma
Publication date: Available online 21 June 2019Source: Photodiagnosis and Photodynamic TherapyAuthor(s): Xinying Li, Liuchang Tan, Huiling Kou, Junbo Zhang, Yuanyuan Wang, Guolin Li, Yuangang LuAbstractBackgroundIn recent years, photodynamic therapy (PDT) is a kind of technique for treating non-melanoma skin cancers in clinical practice compared with traditional methods such as surgical operation, chemotherapy, radiotherapy, and the immunity treatment, etc. PDT offer comprehensive alternatives to...
ScienceDirect Publication: Photodiagnosis and Photodynamic Therapy
1d

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου

Translate